Pioneering Cell & Exosome Therapies for Rare Diseases | Capricor Therapetics (CAPR) Dr. Linda Marbán скачать в хорошем качестве

Pioneering Cell & Exosome Therapies for Rare Diseases | Capricor Therapetics (CAPR) Dr. Linda Marbán

Join us on BioTech Health X as we sit down with Dr. Linda Marbán, CEO, and AJ Bergmann, CFO, of Capricor Therapeutics (NASDAQ: CAPR). They'll discuss their groundbreaking work developing cell and exosome-based therapies for rare diseases. Key Highlights: Deramiocel (CAP-1002): Learn about Capricor's lead candidate, deramiocel, and its promising results in treating Duchenne muscular dystrophy (DMD). Phase 3 Clinical Trials and FDA Meeting: Get the latest updates on deramiocel's Phase 3 clinical development and the upcoming Pre-BLA meeting with the FDA. StealthX™ Platform: Discover how Capricor is leveraging exosome technology to develop innovative treatments for a range of diseases. Russell 2000® Index Inclusion: Understand the significance of Capricor joining the Russell 2000® Index. Future Outlook: Hear from Dr. Marbán and Mr. Bergmann about Capricor's vision for the future and their commitment to transforming the treatment landscape for rare diseases. Don't miss this insightful conversation with the leaders of Capricor Therapeutics! About Capricor Therapeutics Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of the company's innovation is the lead product candidate, deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). Capricor is also harnessing the power of their exosome technology, using the company's proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, they stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. 🌐 Follow Us: Website: https://BioTechHealthX.com X: https://x.com/BioTechHealthX Facebook:   / biotechhealthx   LinkedIn:   / biotechhealthx   💼 For business inquiries: Contact@BioTechHealthX.com #biotech #rarediseases #celltherapy #exosomes #CapricorTherapeutics